Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
+44 7868 792050
ISSN: 2329-8790
+44 7868 792050
John Sarantopoulos
Tanzania
Review Article
Role of Novel Oral Anticoagulants in Primary and Secondary Thromboprophylaxis in Cancer
Author(s): Elizabeth Bowhay-Carnes, Subrata Haldar, Anand Karnad, John Sarantopoulos and Sumit MadanElizabeth Bowhay-Carnes, Subrata Haldar, Anand Karnad, John Sarantopoulos and Sumit Madan
The development of venous thromboembolism is one of the major causes of morbidity and mortality in patients with cancer. The standard treatment of deep venous thrombosis or pulmonary embolism occurring in patients with active malignancy remains the use of low molecular weight heparins. However, in clinical practice, practitioners are frequently asked about the efficacy and safety of various new oral anticoagulants in cancer patients. In the United States, there are currently 4 different novel oral anticoagulants commercially available with the indication of the treatment of acute venous thromboembolism. These include dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa). Use of these new medications is appealing due to the ease of administration, avoidance of injections, ability to use in patients with decreased renal or liver function, and consistent.. View More»
DOI:
10.4172/2329-8790.1000222